AU Patent

AU2022268962A1 — Ras inhibitors for the treatment of cancer

Assigned to Revolution Medicines Inc · Expires 2023-12-14 · 2y expired

What this patent protects

The invention features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.

USPTO Abstract

The invention features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.

Drugs covered by this patent

Patent Metadata

Patent number
AU2022268962A1
Jurisdiction
AU
Classification
—
Expires
2023-12-14
Drug substance claim
No
Drug product claim
No
Assignee
Revolution Medicines Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.